Oric Pharmaceuticals
Daniel Holycross is an accomplished scientist with extensive experience in process chemistry. Currently serving as a Senior Scientist at ORIC Pharmaceuticals Inc. since September 2022, Daniel previously held the position of Senior Research Associate at Gilead Sciences from January 2017 to September 2022. Daniel holds a Master of Science in Organic Chemistry from the University of Illinois Urbana-Champaign (2014 - 2016) and a Master of Science in Chemistry from Central Michigan University (2012 - 2014), where Daniel also earned a Bachelor of Science in Chemistry (2007 - 2011).
This person is not in the org chart
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.